A detailed history of Kennedy Capital Management, Inc. transactions in Exact Sciences Corp stock. As of the latest transaction made, Kennedy Capital Management, Inc. holds 133,859 shares of EXAS stock, worth $6.75 Million. This represents 0.21% of its overall portfolio holdings.

Number of Shares
133,859
Previous 35,035 282.07%
Holding current value
$6.75 Million
Previous $1.48 Million 515.81%
% of portfolio
0.21%
Previous 0.03%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$42.43 - $70.83 $4.19 Million - $7 Million
98,824 Added 282.07%
133,859 $9.11 Million
Q2 2024

Aug 14, 2024

BUY
$41.33 - $74.26 $1.45 Million - $2.6 Million
35,035 New
35,035 $1.48 Million
Q2 2022

Aug 10, 2022

SELL
$35.61 - $76.23 $171,070 - $366,208
-4,804 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$57.56 - $82.54 $57,962 - $83,117
1,007 Added 26.52%
4,804 $336,000
Q4 2021

Feb 14, 2022

SELL
$72.5 - $100.68 $16,820 - $23,357
-232 Reduced 5.76%
3,797 $296,000
Q3 2021

Nov 15, 2021

SELL
$90.24 - $124.05 $15,792 - $21,708
-175 Reduced 4.16%
4,029 $385,000
Q2 2021

Aug 16, 2021

BUY
$93.66 - $139.27 $13,206 - $19,637
141 Added 3.47%
4,204 $523,000
Q1 2021

May 14, 2021

BUY
$116.57 - $155.01 $70,757 - $94,091
607 Added 17.56%
4,063 $535,000
Q4 2020

Feb 12, 2021

BUY
$99.61 - $142.12 $70,125 - $100,052
704 Added 25.58%
3,456 $458,000
Q3 2020

Nov 16, 2020

BUY
$72.92 - $102.01 $145 - $204
2 Added 0.07%
2,752 $281,000
Q2 2020

Aug 14, 2020

BUY
$55.75 - $92.75 $153,312 - $255,062
2,750 New
2,750 $239,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $8.93B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Kennedy Capital Management, Inc. Portfolio

Follow Kennedy Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Kennedy Capital Management, Inc. with notifications on news.